Agnieszka Szczerbinska

Dr. Agnieszka Szczerbinska

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
Beata Kasztelan-SzczerbinskaBeata Kasztelan-Szczerbinska
Beata Kasztelan-Szczerbinska
ARAnna Rycyk-Bojarzynska
Anna Rycyk-Bojarzynska
ASAgnieszka Szczerbinska
Agnieszka Szczerbinska
HCHalina Cichoz-Lach
Halina Cichoz-Lach
Primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC) are rare immune-related cholangiopathies with still poorly explained pathogenesis. Although triggers of chronic inflammation with subsequent fibrosis that affect cholangiocytes leading to obliteration of bile ducts and conversion to liver cirrhosis are unclear, both disorders are regarded to be multifactorial. Different factors can contribute to the development of hepatocellular injury in the course of progressive cholestasis, including (1) body accumulation of bile acids and their toxicity, (2) decreased food intake and nutrient absorption, (3) gut microbiota transformation, and (4) reorganized host metabolism. Growing evidence suggests that intestinal microbiome composition not only can be altered by liver dysfunction, but in turn, it actively impacts hepatic conditions. In this review, we highlight the role of key factors such as the gut–liver axis, intestinal barrier integrity, bile acid synthesis and circulation, and microbiome composition, which seem to be strongly related to PBC and PSC outcome. Emerging treatments and future therapeutic strategies are also presented.

Verified
Journal Article
Open access
PDF file
ASAgnieszka Szczerbinska
Agnieszka Szczerbinska
Beata Kasztelan-SzczerbinskaBeata Kasztelan-Szczerbinska
Beata Kasztelan-Szczerbinska
ARAnna Rycyk-Bojarzynska
Anna Rycyk-Bojarzynska
JKJanusz Kocki
Janusz Kocki
HCHalina Cichoz-Lach
Halina Cichoz-Lach
Hemochromatosis (HC) is the main genetic disorder of iron overload and is regarded as metal-related human toxicosis. HC may result from HFE and rare non-HFE gene mutations, causing hepcidin deficiency or, sporadically, hepcidin resistance. This review focuses on HFE-related HC. The illness presents a strong biochemical penetrance, but its prevalence is low. Unfortunately, the majority of patients with HC remain undiagnosed at their disease-curable stage. The main aim of HC management is to prevent iron overload in its early phase and remove excess iron from the body by phlebotomy in its late stage. Raising global awareness of HC among health staff, teaching them how not to overlook early HC manifestations, and paying attention to careful patient monitoring remain critical management strategies for preventing treatment delays, upgrading its efficacy, and improving patient prognosis.

25 February 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
ASAgnieszka Szczerbinska
Agnieszka Szczerbinska
Beata Kasztelan-SzczerbinskaBeata Kasztelan-Szczerbinska
Beata Kasztelan-Szczerbinska
ARAnna Rycyk-Bojarzynska
Anna Rycyk-Bojarzynska
HCHalina Cichoz-Lach
Halina Cichoz-Lach
Hereditary hemochromatosis (HH) is the main genetic cause of iron overload and is regarded as metal-related human toxicosis. HH may result from HFE and non-HFE gene mutations causing hepcidin deficiency or hepcidin resistance. The disorder has a high biochemical penetrance, but a low clinical prevalence. Unfortunately, the majority of patients with HH remain undiagnosed at their disease-curable stage. The main aim of HH therapy is to prevent iron overload in the early-phase disease and elimination of excess iron from the body by phlebotomy in its late stage. Raising global awareness of HH among health professionals, their training to pay attention to early HH signs and symptoms, and strict patient monitoring are critical management strategies for preventing treatment delays, upgrading its efficacy, and improving patient prognosis.

Verified
Journal Article
Open access
PDF file
ASAgnieszka Szczerbinska
Agnieszka Szczerbinska
JRJacek Roliński
Jacek Roliński
ASAgata Surdacka
Agata Surdacka
HCHalina Cichoz-Lach
Halina Cichoz-Lach
Alcohol-associated liver disease (ALD) is the leading cause of liver-related mortality. In ALD, excessive inflammatory response may induce a massive loss of hepatocytes and lead to irreversible liver damage with progressive fibrosis. Chemokines stimulate the migration of immune cells to the site of inflammation and contribute to the inflammatory cascade that may result in organ failure. We aimed to investigate blood concentrations of CXCL9/MIG, CXCL10/IP-10, and CXCL16 chemokines and their diagnostic and prognostic significance in patients with ALD. In a prospective observational study, 88 individuals were recruited, including 63 patients with ALD (44 men and 19 women, aged 48.49 ± 10.88) and 25 healthy control volunteers matched for age, sex, and ethnicity. In blood samples, concentrations of CXCL9/MIG, CXCL10/IP-10, and CXCL16 were measured using immunoenzymatic ELISAs. Correlations were examined between CXCL levels and (a) traditional inflammatory markers (C-reactive protein, white blood cell count, neutrophil count, lymphocyte count, and neutrophil-to-lymphocyte ratio-NLR) and (b) liver dysfunction severity scores: Child–Turcotte–Pugh (CTP), MELD-NA, MELD 3.0, and modified Maddrey’s discriminant function (mDF). Patients’ survival within 30 days of hospital admission was recorded for analysis. CXCL capabilities in predicting the severity of liver dysfunction and ALD outcome were validated. ALD patients showed significant systemic upregulation of all studied chemokines compared to the control group. Patients with advanced liver disease, classified as MELD-Na ≥ 20, MELD3.0 > 19, and CTP class C, as well as poor short-term outcomes, presented with significantly higher CXCL9 and CXCL10 levels compared to their counterparts. ALD non-survivors had significantly higher concentrations of all studied CXCLs in comparison to controls. Positive correlations between CXCL16 and CRP, leukocytosis, neutrophils, and NLR were confirmed (0.67; 0.46; 0.48; 0.54, respectively). Although none of the chemokines correlated with ALT activity, CXCL9, CXCL10, and CXCL16 showed positive correlations with bilirubin and alkaline phosphatase and inverse correlations with albumin levels. Our findings revealed the diagnostic and prognostic value of the studied CXCLs in ALD. In particular, CXCL9 and CXCL10 may have potential for discrimination of severe liver dysfunction and poor short-term prognosis. Further multicenter studies are required to confirm our results.

18 September 2024 in Annals of Agricultural and Environmental Medicine
Verified
Journal Article
Open access
ARAnna Rycyk-Bojarzynska
Anna Rycyk-Bojarzynska
KCKinga Knop- Chodyła
Kinga Knop- Chodyła
ASAgnieszka Szczerbinska
Agnieszka Szczerbinska
Beata Kasztelan-SzczerbinskaBeata Kasztelan-Szczerbinska
Beata Kasztelan-Szczerbinska
HCHalina Cichoz-Lach
Halina Cichoz-Lach
JSJustyna Szumiło
Justyna Szumiło
Granular cell tumour (GCT) or Abrikossoff tumour, is a rare submucosal neoplasm orginating from Schwann cells, and accounts for 0.03% of all submucusal tumours. Only 8% of GCTs occur in the gastrointestinal tract, mostly in the esophagus. Diagnosis of granular cell tumour is exceptionally rare....

15 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
ASAgnieszka Szczerbinska
Agnieszka Szczerbinska
JDJulia Dolinkiewicz
Julia Dolinkiewicz
JKJan Kamiński
Jan Kamiński
SRSebastian Rurka
Sebastian Rurka
Beata Kasztelan-SzczerbinskaBeata Kasztelan-Szczerbinska
Beata Kasztelan-Szczerbinska
Background: eosinophilic esophagitis (EoE) and Schatzki ring are distinct conditions, but their clinical presentation may resemble one another. Moreover, they can closely mimic the third common disorder, that is gastroesophageal reflux disease (GERD) making a patient diagnostic approach even more challenging. Aim of the study: presentation of a case with EoE with coexistence of Schatzki ring and related subject literature review. Materials and methods: one case of non-specific GERD symptoms and gradual dysphagia development. Literature review of existing reports and data regarding epidemiology, clinical presentation, and diagnostic approach to patients with EoE suspicion. Presentation of the current guidelines on disease management. Additionally, we discuss the medical challenges that may occur in patients with esophageal dysfunction and highlight that further studies are warranted to better explain EoE's long-term impact on patient outcomes. Conclusions: EoE has become increasingly recognized over the last decade, but may still create a clinical challenge. Its symptoms vary with age, and pathogenesis is still not fully explained. Experts in the field recommend special criteria for diagnosing EoE, which should be followed to establish the proper diagnosis. Further studies are warranted to better explain EoE's pathophysiology and long-term impact on patient outcomes.